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http://www.biomedcentral.com/1471-2369/13/131RESEARCH ARTICLE Open AccessReduced incidence of end stage renal disease
among the elderly in Denmark: an observational
study
James G Heaf1* and Sonja Wehberg2Abstract
Background: A number of studies during the nineties have shown that antihypertensive therapy, particularly using
RAS blockade, can reduce uremia progression, and ESRD incidence.
Methods: National incidence rates were studied of end stage renal disease (ESRD) for Denmark between 1990 and
2011, and of national prescription of antihypertensive drugs between 1995 and 2010, in order to investigate
whether prescription rates had changed, and whether the expected change in ESRD had materialized. The Danish
Nephrology Registry (DNR) is incident and comprehensive. Incidence rates were classified according to renal
diagnosis.
Results: ESRD incidence was constant for age groups <60 years. Incidence rates rose during the nineties for all
cohorts >60 years. Since 2001 rates for subjects 60–70 years have fallen from 400 ppm/yr to 234, and since 2002 for
subjects 70–80 years from 592 to 398. The incidence of patients >80 years has increased to 341. The falling
incidence for patients 60–80 years was distributed among a number of diagnoses. Since 1995 national
antihypertensive drug therapy has increased from 24.5 defined daily doses (DDD)/citizen/yr to 101.3, and the
proportion using renin-angiotensin system (RAS) blockade from 34 to 58%.
Conclusions: This national study has shown a reduction in actively treated ESRD incidence among patients aged
60–80 years. It is possible that this is the result of increased antihypertensive prescription rates, particularly with RAS
blockade. If it is assumed that therapeutic intervention is the cause of the observed reduced incidence, ESRD
incidence has been reduced by 33.8 ppm/yr, prevalence by 121 ppm, and ESRD expenditure by 6 €/citizen/yr.
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During the nineties, a number of studies were published,
showing that antihypertensive therapy in patients with
chronic kidney disease (CKD) delayed the progression of
uremia. Whether intensive antihypertensive therapy, with
the aim of reducing blood pressure to below 130/80 (as
opposed to conventional therapy) is per se effective, is still
controversial. The original MDRD study [1], comparing
low and high intensity antihypertensive therapy, found
that beneficial effects were limited to patients with pro-
teinuria >1 g/day, and other large studies, such as the* Correspondence: heaf@dadlnet.dk
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distribution, and reproduction in any mediumREIN-2 [2] and AASK [3] trials, have failed to demon-
strate an overall effect of intensive treatment. However,
the ESCAPE trial of 385 children with CKD, demonstrated
a 35% reduction in uraemia progression. Anithypertensive
therapy, regardless of type, reduces proteinuria [1,3]. In
contrast, there is no doubt that renin-angiotensin system
(RAS) blockade has a specific protective effect over and
above other antihypertensive agents, presumably because
of its extra anti-inflammatory and anti-proteinuric effects.
Early studies suggested that uraemia progression could be
delayed by 35% [4,5]. Since then a number of large studies
have shown that RAS blockade prevents the development
of diabetic nephropathy [6] and reduces uraemia progres-
sion by 30-40% [7-10]. These studies have recently been
reviewed [11]. The effect is present both in proteinuricentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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greater the degree of proteinuria and the achieved reduc-
tion in proteinuria. We hypothesized that these papers will
have led to national antihypertensive prescription changes
which would in turn result in a reduction in the incidence
of end stage renal disease (ESRD).
Results
While the national population only rose by 8.3% during
the study period, considerable changes in the age struc-
ture were seen. The population aged 60–69 years
increased from 492,000 to 683,000 (38.9%), 70–79 years
from 367,000 to 386,000 (5.3%), and over 80 from
188,000 to 227,000 (21.5%).
The age of the oldest incident ESRD patient in the
registry rose almost linearly from 75.3 years in 1985 to
81.8 in 1990 and 95.1 in 2007, after which it stabilized,
an average increase of 7.6 months/year. The average age
rose from 51.6 ±15.9 to 61.9 ± 16.1 in 2001 and to 64.5
±18.2 years in 2010. The Charlson Comorbidity Index
remained steady for patients <50 years, but increased
significantly for older age groups (Table 1, Figure 1).
Data concerning national prescription rates for the
four most common antihypertensive drugs were avail-
able for 1995–2010 (Figure 2). During this period con-
sumption rose from 24.5 to 101.3 DDD/capita/year, a
four-fold increase. The proportion of consumption
attributed to renin-angiotensin system (RAS) blockers
rose from 34 to 59%.
The incidence of ESRD is shown in Table 2, and the
absolute patient numbers in Table 3. The incidence of
patients <60 years remained approximately constant dur-
ing the entire period of observation (Table 2). A fall in
incidence of 19% between 2001 and 2011 for this group
was not significant. Since 2001 the ESRD incidence has
fallen by 7% among 40–49 year olds, and 26% among
50-59-year-olds. These changes were not significant. The
incidence of patients 60–70 years (Figure 3) rose from
167 patients per million of population (ppm) in 1990 to
400 ppm in 2001, and then fell steadily to 234 ppm, a
42% fall (p < 0.01). The incidence of patients 70–80 yearsTable 1 Average Charlson Comorbidity Index and age: time t
Year
Age 1990 2000 20
0-19 2,00 ±0,2a 2,17 ±0,4 2,13
20-29 2,97 ±1,3 3,32 ±1,5 2,59
30-39 3,96 ±1,6 3,36 ±1,6 3,33
40-49 3,18 ±1,7 3,53 ±1,6 3,44
50-59 3,47 ±2,0 4,32 ±2,1 4,22
60-69 3,51 ±1,5 4,24 ±2,0 5,01
70-79 3,36 ±1,8 4,20 ±1,9 5,08
≥80 2,67 ±0,8b 4,56 ±2,5 4,86rose from 106 ppm in 1990 to 593 in 2002, and then fell
to 398, a 33% fall (p < 0.03). Active treatment of patients
over 80 years was virtually nonexistent at the beginning
of the study period, rose slightly to 58 ppm in 1997, and
then rose rapidly to 557 ppm in 2007. It has since fallen
to 341 ppm, a 39% fall (NS). The secular trend for inci-
dence for the years 2000–2011 was significant for those
aged 60–70 (r =−0.91, p < 0.001), but not for patients
70–80 years (r =−0.45, NS).
The contributions of risk reduction population struc-
ture changes and population number changes is shown
in Table 4. For all groups, a fall in incidence was noted,
which was independent of changes in population num-
ber and structure. The fall was greatest for patients 60–
80 years.
In order to analyze which renal diagnoses had experi-
enced the highest fall in incidence, incidence rates for
the years 2000–01 were compared with the years 2009–
2010 for common renal diagnoses. The results are
shown in Table 5. Improvements were seen over a wide
range of diagnoses, with no clear distinction between
proteinuric (e.g. diabetic nephropathy and glomerulo-
nephritis) and non-proteinuric (e.g. CIN and polycystic
renal disease). A post-hoc analysis of sub-diagnoses in
the diagnosis group “Other”, showed falls in most sub-
groups, but the number of patients in each subgroup did
not permit statistical analysis. However, the incidence of
patients with vasculitis (ICD-10 codes M30.x and M31.x)
among patients aged 60–79 fell 58% from 20.8 ppm/year
to 8.7 (p< 0.03).
Discussion
The incidence of actively treated ESRD has increased
continuously since the start of maintenance dialysis ther-
apy in the sixties. This has been largely driven by a
steady increase in take-on rates. There are two reasons
for this. Firstly, economic growth and a steady reduction
in the costs of dialysis, mean that health services have
been able to afford treating more patients. Secondly, the
results of treating patients of increasingly high age and
morbidity, in particular DM, have improved, such thatrends
10 Correlation coefficient Significance
±0,4 NS
±1,2 NS
±1,9 NS
±1,8 NS
±2,2 0,11 <0.001
±2,4 0,15 <0,001
±2,0 0,21 <0,001
±2,0 0,17 <0,001
60 69years 70 79years >80
years
Figure 1 Changes in Charlson Comorbidity Index over time, according to age group.
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tern can be seen in this national survey. During the
period, a linear increase in the age of the oldest patient
in the registry was seen, and the age-adjusted morbidity
increased. This increase, approximating 6 months per
year, was far greater than the increase in expected life
expectancy of the background population. During the
nineties, increased incidence rates for 60-80-year-olds
and diabetics [12] were seen. After 2000, in response to
encouraging treatment results [13], the incidence of 80-
year-olds rapidly increased, while the incidence of dia-
betics stabilized [12]. Thus, it is highly likely that the ini-
tial rise in incidence in elderly age groups is an
expression of these secular trends. The increase in inci-
dence rates for Type 2 diabetics over the age of 70 after
2001 is probably also part of this trend. One would
therefore expect that incidence rates at some point
would stabilize at a higher level.Figure 2 National consumption of the commonest antihypertensive aThe present study shows that ESRD incidence among
patients <40 years has remained stable for 20 years.
Since 2001 the ESRD incidence has fallen by 7% among
40–49 year olds, and 26% among 50-59-year-olds. These
changes were not significant. Since 2001 the ESRD inci-
dence among 60-70-year-olds has fallen by 42%, and 70-
80-year-olds since 2002 by 33%. The Riskdiff analysis
(Table 4) shows that these changes are independent of
population structure. A recent fall in incidence since
2007 of 39% among patients older than 80 years is too
recent to be meaningful. It could be due to a real in-
crease in incidence similar to the 60–80 year-olds, or a
waning enthusiasm by primary health carers for referring
these often frail patients for treatment. This is in con-
trast with other national results [14,15] which have
merely showed a stabilization in these age groups. We
believe this to be one of the first cases of a national re-
duction in ESRD incidence in the absence of social orgents 1995–2010.
Table 2 Incidence of ESRD 1990–2011 according to age, and standardized rate (patients per million, ppm)
Age (years) Standardised Population
(thousand)Year 0-19 20-29 30-39 40-49 50-59 60-69 70-79 ≥80 Rate (ppm)*
1990 6 45 32 101 112 167 106 5 64 5,135
1991 9 34 43 75 156 207 140 0 71 5,146
1992 11 24 64 69 150 153 153 5 67 5,162
1993 14 34 56 106 182 262 251 25 95 5,181
1994 7 38 80 71 145 231 225 30 84 5,197
1995 15 47 53 104 136 278 274 39 96 5,216
1996 9 35 60 89 145 281 323 39 96 5,251
1997 8 34 70 86 167 287 357 58 103 5,275
1998 14 32 50 98 162 278 421 116 108 5,295
1999 6 31 64 105 150 383 442 187 122 5,314
2000 10 26 67 120 186 351 479 230 129 5,330
2001 11 28 49 90 191 400 567 300 137 5,349
2002 9 22 60 80 143 366 593 319 130 5,368
2003 6 43 43 96 152 367 565 290 131 5,384
2004 14 35 45 110 153 345 516 343 130 5,398
2005 11 16 48 73 176 303 497 308 117 5,411
2006 13 21 41 84 133 289 509 381 117 5,427
2007 13 26 63 94 184 319 551 557 140 5,447
2008 10 29 32 85 146 268 528 471 120 5,476
2009 16 49 45 82 167 266 507 445 125 5,511
2010 6 27 53 70 154 253 401 422 108 5,535
2011 5 22 53 84 141 234 398 341 102 5,561
*Based on population structure in 1990.
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valent dialysis patients in Denmark has now fallen by
5% since 2008. Taiwan has also noted a fall in ESRD
incidence from 432 to 384 ppm between 2005 and
2008; this has not however yet resulted in a fall in
prevalence [15].
During the nineties, a number of possibly modifiable
factors in the progression of uraemia were identified.
Aggressive treatment of hypertension is probably im-
portant [1,16]. RAS blockade by ACE-I and A2A were
shown to have specific nephroprotective properties, in
particular in patients with diabetes and proteinuria
[4,5,9,10,17,18]. A protective effect of protein restriction
has been suggested [19], as has a nephrotoxic effect of
tobacco [20]. Increased use of these prophylactic mea-
sures would be expected to reduce ESRD incidence.
Figure 2 shows that the prevalence of antihypertensive
therapy, and in particular RAS blockade in the general
population has indeed increased substantially, to a level
of 0.27 DDDs/capita/year. The percentage of non-
smokers (or irregular) has increased from 58 to 77% be-
tween 1995 and 2008 [7]. There is no evidence that the
incidence of hypertension has increased in Denmark;
thus the increased drug use is probably an expression of
more intensive individual therapy. This study has onlydocumented an increase in general antihypertensive
therapy, in particular RAS blockade, and a reduction in
ESRD incidence among the elderly. This being an obser-
vational study, any discussion about causality must be
purely speculative, but it is possible that the observed
decrease in ESRD incidence is an expected consequence
of the intensified prophylaxis. If this is so, there appears
to be a lag time of at least 5 years between a change in
antihypertensive therapy and a decrease in incidence.
This is not surprising: in order to delay ESRD signifi-
cantly, treatment has to be initiated while the patient
still has a significant renal function. During the period of
observation, there were no governmental changes in the
organization or financing of ESRD treatment. All patients
are treated at hospital-based, publicly financed nephrology
centers. There has been an increased awareness of the im-
portance of predialysis nephrology care, and today all
patients with a GFR below 30 ml/min are recommended
specialist care. This may have contributed to the fall in
ESRD rates, independently of concurrent antihypertensive
therapy and RAS blockade. In common with inter-
national trends, there has probably been a tendency
to start dialysis at a higher level of GFR since 2000;
this would a priori increase the number of ESRD
patients slightly.
Table 3 Incidence of ESRD 1990–2011 according to age
(absolute numbers)
Age (years) Total
Year 0-19 20-29 30-39 40-49 50-59 60-69 70-79 ≥80
1990 9 36 24 77 60 82 39 1 328
1991 11 27 32 58 85 100 52 0 365
1992 14 19 48 55 83 73 57 1 350
1993 17 28 42 83 104 124 93 5 496
1994 9 30 61 56 86 108 83 6 439
1995 18 37 41 81 83 129 101 8 498
1996 11 28 47 68 96 130 119 8 507
1997 11 26 56 66 113 134 131 12 549
1998 17 25 42 72 114 130 154 24 578
1999 8 24 53 79 108 182 161 39 654
2000 12 21 55 91 138 168 174 48 707
2001 14 20 41 67 144 195 204 63 748
2002 11 15 49 61 108 183 210 69 706
2003 8 31 37 72 116 189 200 63 716
2004 19 23 36 85 116 185 182 75 721
2005 14 11 40 57 133 170 174 68 667
2006 17 13 32 68 99 170 179 85 663
2007 18 16 48 75 134 198 197 125 811
2008 14 18 24 69 105 172 193 106 701
2009 21 33 34 67 121 179 188 102 745
2010 8 19 41 60 112 175 157 104 676
2011 7 14 39 68 101 160 154 78 621
Heaf and Wehberg BMC Nephrology 2012, 13:131 Page 5 of 8
http://www.biomedcentral.com/1471-2369/13/131Considerable changes have occurred in the back-
ground population between 1990 and 2011. The average
longevity has increased from 72.2 to 77.8 years for
males, and 77.3 to 81.6 for females [21]. While increased
longevity will of course be expected to increase the abso-
lute numbers of elderly patients, it will not in itself affect
the incidence, expressed as a fraction of the population
at risk. The Riskdiff analysis shows that the observed
changes are real and independent of any change in
population structure. It shows that the evolution of the
population 60–80 years would have lead to a rise ofFigure 3 Incidence of ESRD in patients >60 years 1990–2011.incidence of 16% while the observed incidence was
−21%. The underlying risk fell by 36%. Ischaemic heart
disease as a cause of death fell from 25.6% of all deaths
to 9.2%, and cerebrovascular disease from 9.1% to 6.9%.
These changes could also partly be related to more in-
tensive antihypertensive therapy. It is difficult to predict
how these changes might affect ESRD incidence: on the
one hand, since cardiac and renal disease are often
related, with common etiologies such as diabetes, ath-
erosclerosis and hypertension, a better cardiac survival
might lead to more patients surviving to renal failure; on
the other hand, the prophylactic treatments that reduce
the incidence of heart disease might also reduce the inci-
dence of renal disease.
Two findings were surprising. The fall in incidence was
distributed between different renal diagnoses, without any
clear distinction between proteinuric and non-proteinuric
diseases. A change in coding practices during the period of
observation cannot be excluded, but since the diagnoses
were made by a small group of nephrologists, using stand-
ard ERA-EDTA definitions, we consider this unlikely. Also,
the fall in incidence was mainly confined to patients over
the age of 60. While ESRD incidence was lower for patients
aged 30–59 was lower in 2011 than 2001, the difference
was smaller and non-significant, partly because of the small
number of patients in these age groups. There are several
possible explanations for this apparent difference: some
diagnoses, common among younger patients, such as poly-
cystic renal disease and hereditary disorders, may be less
amenable to prophylaxis; early diagnosis and prophylaxis
may be rarer among younger patients; it is possible that
long-term therapy is required to make a noticeable differ-
ence. Antihypertensive therapy has been shown in the ES-
CAPE study to also be effective in children [16]. This is a
recent study, which cannot have affected previous therapy;
no data is available concerning antihypertensive therapy
among children in this population. A further disadvantage
of this study is that data concerning antihypertensive use
was only available after 1995, and only as DDDs, rather
than number of patients being treated.
Not all health indicators have moved in the right dir-
ection. The number of obese adults (body mass index
>30 kg/m2) has risen from 5.5% in 1987 to 7.6% in 1994
and to 13.4% in 2010. It is thus all the more remarkable
that the expected epidemic in diabetic nephropathy has
not occurred, and that the incidence of type 2 diabetic
nephropathy is stabilised. Thus, the theory that intensive
prophylactic intervention can reduce the incidence
of diabetic nephropathy seems to have been justified
in practice.
It is possible that unidentified factors could have
contributed to the fall, e.g. a reduction in consumption
of nephrotoxic drugs or an improvement in the uro-
logical treatment of patients with post-renal uremia.
Table 4 RiskDiff analysis of contributing factors to changes in incidence 2001 vs. 2011
ESRD incidence (p.p.m) Total change Contributing factor
Change in risk Change in population structure Change in population size
Age group (years) 2001 2011 No. % No. % No. % No. %
0-110 140 112 −127 −17.0 −213 −28.5 62 8.3 24 3.2
0-80 133 102 −142 −20.7 −223 −32.6 61 8.9 20 2.9
0-60 67 54 −57 −19.9 −53 −18.4 −3 −1.0 −1.5 −0.5
60-80 472 294 −85 −21.3 −142 −35.6 −9 −2.2 66 16.5
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contributed to the fall in vasculitis incidence. It is even
possible that the initial increase in incidence seen among
patients over 70 years is partly caused by a postpone-
ment of ESRD among patients 60–70 years to a later
age, the real fall in incidence thereby being exaggerated.
If one assumes that there is a causal connection and that,
without intervention, incidence among 60-70-year-olds
would have remained at 400 ppm and among 70-80-year-
olds at 592, a rough estimate of the possible economicTable 5 Incidence of ESRD (ppm/year) in 2000–01 compared t
Renal diagnosis Age group 2000-01
No. Incidence
Small 60-69 72 74.5
70-79 119 165.3
Combined 191 113.3
Glomerulonephritis 60-69 41 42.4
70-79 16 22.2
Combined 57 33.8
Chronic Interstitial 60-69 48 49.7
70-79 49 68.1
Combined 97 57.5
Polycystic 60-69 25 25.9
70-79 12 16,7
Combined 37 21.9
Hypertensive 60-69 40 41,4
70-79 46 63,9
Combined 86 51.0
Type 1 DM 60-69 28 29.0
70-79 15 20.8
Combined 43 25.5
Type 2 DM 60-69 53 54,9
70-79 51 70,8
Combined 103 61.7
Other 60-69 59 61.1
70-79 70 97.2
Combined 129 76.5
Total 60-69 366 378.9
70-79 378 525.0
Combined 744 441.3benefits of prophylaxis can be made. Further assumptions
are required for this calculation: the mean survival after
ESRD is 4.3 and 2.5 years respectively (DNR average 2000–
2010); the average cost is €50,000/year. It then follows that
ESRD incidence has been reduced by 33.8 ppm/year, ESRD
prevalence by 121 ppm and ESRD expenditure by approxi-
mately €6 per capita/year. Drug expenditure needs to be
subtracted from this to calculate the net economic benefit.
For commonly used ACE inhibitors this is however less
than 10 cents/day.o 2009–10, according to age group and renal diagnosis
2009-10 % Change Sig.
No. Incidence
94 70.7 −5 NS
100 134.0 −19 NS
194 93.4 −18 NS
35 26.3 −38 NS
17 22.8 3 NS
52 25.0 −25 NS
44 33.1 −34 NS
34 45.6 −33 NS
78 37.6 −35 NS
21 15.8 −39 <0.05
11 14.7 −12 NS
32 15.4 −30 NS
32 24.1 −42 NS
53 71.0 11 NS
85 40.9 −20 NS
20 15.0 −48 NS
11 14.7 −29 NS
31 14.9 −42 NS
71 53.4 −3 NS
62 83.1 17 NS
133 64.1 4 NS
31 23.3 −62 <0.002
52 69.7 −28 NS
83 40.0 −48 <0.001
348 261.7 −31 <0.001
340 455.8 −13 NS
688 331.4 −25 <0.001
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During the period of observation, a significant fall in
ESRD incidence in the population between 60–80 years
age was seen, and also an increase in prescription rates
for antihypertensive drugs, particularly RAS blockade. It
is possible that these two phenomena are connected.
The findings suggest that ESRD is a preventable disease.
Methods
All patients resident in Denmark, and thus possessing
a national identity number, starting active treatment
for ESRD between 1.1.1990 and 31.12.2011 were
included in the study. Their data were extracted from
the following databases:
1) The Danish Nephrology Registry (DNR) contains
data from all patients starting active treatment in
Denmark. The database is incident, prospective
and has been comprehensive since 1.1.1990.
Cross-checks with performed dialyses registered in
the National Patient Registry show that >99% of
all patients with ESRD are included. A patient is
regarded as having ESRD if (a) the nephrologist
considers him/her to have ESRD on the day of
first active treatment or later; (b) a renal
transplant is performed; (c) there is some doubt
regarding the reversibility of the uraemia (e.g.
crescentic glomerulonephritis, acute
tubulointerstitial nephropathy), but the patient has
received at least 90 days of dialysis. A recent
quality assessment study has shown that the risk
of not being included in the registry is less than
1% ([22]). Patient sex, renal diagnosis, and age at
ESRD were noted.
2) Discharge diagnoses for all admissions to hospital
between 1977–2010 were extracted from the
National Patient Registry (LPR). The Charlson
Comorbidity Index (CCI) [23] at ESRD was
calculated. All patients received two CCI points for
uremia/ESRD regardless of whether they had
previously been admitted for this condition.
3) National population statistics were extracted from
the National Population Registry (Statistics
Denmark).
4) National prescription rates for antihypertensive
drugs, excluding diuretics, between the years
1995–2010 were extracted from the Danish
Medicines Agency. Prescriptions were classified as
β-blockers, calcium antagonists, angiotensin
converting enzyme inhibitors (ACE-I) and
angiotensin receptor blockers (A2A). Consumption
of other antihypertensive classes was minimal.
Consumption was assessed as number of defined
daily doses (DDD) 1000 citizens/day.ESRD incidence rates were calculated for different age
groups and renal diagnoses. Renal diagnoses up to
31.12.2010 were categorized as shrunken kidneys (ICD-10
code N18.x, Q60.5), chronic glomerulonephritis (N02.
x-N07.x), chronic interstitial nephritis (CIN) (N11.x-N15.
x, N20.x, N31.9, Q62.x), polycystic renal disease (Q61.x)
hypertensive (I12.x), type 1 diabetic (DM) (E10.x), type 2
diabetic (E11.x), other.
Statistics
Incidence rates between years were compared using the
χ2 test. Secular trends were analysed using Pearsson
product–moment correlation.
A post-hoc analysis was performed to compare inci-
dence rates between 2001 and 2011. The RiskDiff pro-
gram [24] is a tool can be useful to study the differences
in the incidence or mortality observed in two given
situations (such as time points, geographical areas, or
males versus females). The method performed splits the
observed differences into three components: (1) the risk
itself, (2) difference attributed to changes in the popula-
tion size and (3) difference attributed to changes in
population structure.
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